China's NMPA Accepts Hansoh's B7-H3 Antibody-Drug Conjugate for Small Cell Lung Cancer Review

Chinese drugmaker Hansoh Pharmaceutical announced on September 7 that China's National Medical Products Administration has accepted the biologics license application for HS-20093, an antibody-drug conjugate targeting B7-H3, for the treatment of small cell lung cancer in patients who have already received platinum-based chemotherapy. The drug, also known as risvutatug rezetecan, is one of the most closely watched assets in the Chinese ADC pipeline, in part because its global rights, excluding mainland China, Hong Kong, Macau and Taiwan, were licensed to GSK in December 2023 in a deal that underscored Western appetite for Chinese-developed antibody-drug conjugates. The acceptance moves the drug a step closer to becoming the first B7-H3 ADC approved in any major market for small cell lung cancer.

Key Facts

Hansoh announced the NMPA acceptance in an official statement on September 7, and the Chinese pharmaceutical news site pharmcube bydrug and the venture-capital publication VCBeat both reported the news the same day. The application covers HS-20093 for the treatment of patients with small cell lung cancer whose disease has progressed after platinum-based chemotherapy, a population with limited treatment options and poor prognosis.

The application is supported by ARTEMIS-008, a Phase III trial whose results were first reported in July 2026. Hansoh said in its September 7 statement that ARTEMIS-008 met its primary endpoint of overall survival, showing a statistically significant and clinically meaningful improvement over the comparator, topotecan, a standard chemotherapy used in the relapsed setting. The company described the trial as the first Phase III study in any tumor type to demonstrate an overall survival benefit for a B7-H3-targeted antibody-drug conjugate, a claim that, if confirmed by the presentation of the full data, would establish the drug class as a meaningful new treatment option.

The clinical context explains the urgency. Small cell lung cancer accounts for roughly 15 percent of all lung cancers and is the most aggressive subtype, according to Hansoh's September 7 statement, and the majority of patients relapse after first-line platinum-based chemotherapy. For those patients, the standard options have historically been limited to further chemotherapy or, more recently, a handful of targeted and immunotherapy approaches, and outcomes remain poor, which is why a new agent with a novel mechanism generates interest among oncologists.

The drug's regulatory track record points to its perceived potential. Hansoh said in its September 7 statement that HS-20093 has received 12 regulatory designations globally, including breakthrough therapy designations, orphan drug status and the European Medicines Agency's PRIME scheme, a collection of fast-track labels that reflect the strength of the early data. The drug is built from a fully human anti-B7-H3 monoclonal antibody linked to a topoisomerase I inhibitor payload through a tetrapeptide cleavable linker, a design intended to deliver the cytotoxic payload selectively to tumor cells that express B7-H3. Full results from ARTEMIS-008 are scheduled to be presented at the presidential symposium of the World Conference on Lung Cancer on September 13, according to pharmcube bydrug's September 7 report.

Analysis

What this really means is that the B7-H3 ADC class is close to its first regulatory approval, and Hansoh's HS-20093 is the asset most likely to get there first in small cell lung cancer, a disease where new systemic therapies have been rare and incremental. The NMPA acceptance is not itself a clinical result, but the fact that it rests on an overall survival win against topotecan, rather than a response-rate surrogate, is significant, because regulators and oncologists increasingly want proof that a drug extends life before they change practice. If the full ARTEMIS-008 data hold up at the World Conference on Lung Cancer, HS-20093 will have cleared the highest evidentiary bar available in this setting.

The bigger picture here is that HS-20093 is a test case for the Chinese ADC licensing boom. Over the past several years, Western pharmaceutical companies have paid billions of dollars in upfront fees to license antibody-drug conjugates from Chinese biotechs, on the theory that Chinese developers had become world-class at ADC chemistry while Western companies retained the regulatory and commercial infrastructure to globalize the drugs. GSK's December 2023 deal for HS-20093 was part of that wave, and the drug's progress through the clinic is now a concrete measure of whether those bets are paying off. A positive OS result and a successful filing in China would validate the thesis that Chinese ADC platforms can produce globally relevant medicines, and it would likely accelerate further licensing activity in the class.

The small cell lung cancer indication is a smart first target. B7-H3 is highly expressed in small cell lung cancer, and the relapsed setting is one where the standard of care is weak enough that a new agent can demonstrate a clear advantage without needing to beat an entrenched frontline therapy. The choice also reflects a commercial logic: small cell lung cancer is a smaller market than non-small cell lung cancer, but it is an area of high unmet need where pricing power and regulatory priority are stronger, and a first-in-class approval in this niche can establish the drug and the company for expansion into larger indications later. The 12 regulatory designations HS-20093 has accumulated suggest Hansoh and GSK have been building exactly that expansion path.

Why It Matters

For patients with relapsed small cell lung cancer, the drug represents a potential new standard of care in a setting where options have been limited for decades, and the overall survival benefit reported in ARTEMIS-008, if confirmed, would be the kind of result that changes treatment guidelines. For Hansoh, the acceptance is a commercial milestone that positions the company to capture the China market for the drug on its own, while GSK develops the rest of the world, a split that lets Hansoh retain the value of its home market while sharing the global upside. For GSK, HS-20093, which it codes as GSK5764227, is one of the most important assets in its oncology pipeline, and progress in China de-risks the global development program by generating efficacy and safety data that support filings elsewhere.

For the broader field of antibody-drug conjugates, the result is evidence that B7-H3, a target that has been studied for years without a clear winner, can support a drug with a survival benefit. Several companies have B7-H3 programs in development, and a positive Phase III readout in any tumor type will refocus attention on the class and on the patients most likely to benefit. The September 13 presentation of the full data at the World Conference on Lung Cancer will be the moment the oncology community judges whether the promise of the B7-H3 ADC class is real, and Hansoh's drug will be at the center of that judgment.

Next Up

The immediate milestone is September 13, when the full ARTEMIS-008 results are scheduled to be presented at the World Conference on Lung Cancer, and the strength of the survival data, the safety profile and the magnitude of the benefit will be scrutinized by oncologists and by competitors with their own B7-H3 programs. After that, the next step is the regulatory process in China, where the NMPA's acceptance begins a review that typically takes months and could lead to the first approval of HS-20093 in any market. Watch also for the progress of GSK's global development program under the GSK5764227 code, and for whether the Chinese approval is followed by filings in the United States and Europe, which would confirm that the December 2023 licensing bet has paid off at full scale.